Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is an autoimmune disorder where the body produces anti-receptor antibodies against the α1 subunit of nicotinic acetylcholine receptors. These antibodies damage the neuromuscular junction through three mechanisms: blocking acetylcholine binding sites, cross-linking receptors to trigger their internalization, and inducing postsynaptic membrane breakdown. This prevents acetylcholine from activating muscle contraction.

Myasthenia gravis initially presents with ptosis (drooping eyelids) and diplopia (double vision). As the disease progresses, patients develop dysarthria (speech difficulty) that advances to dysphagia (difficulty swallowing). In severe cases, limb and respiratory muscles become affected, potentially compromising breathing and mobility.

Anticholinesterase inhibitors such as neostigmine, pyridostigmine, and ambenonium block acetylcholinesterase enzyme activity, allowing acetylcholine to accumulate in the synaptic cleft. This increased acetylcholine concentration enhances depolarization of the muscle endplate, improving neuromuscular transmission and restoring muscle strength despite reduced functional receptors.

Thymectomy, surgical removal of the thymus gland, is recommended because the thymus often contains tumors and plays a role in disease development. Thymectomy gradually improves motor symptoms by reducing antibody production and can sometimes lead to complete remission of myasthenia gravis symptoms.

Plasmapheresis removes circulating anti-receptor antibodies from the bloodstream, providing temporary symptom relief in severe cases. Immunosuppressant medications like azathioprine, cyclosporine, and glucocorticoids target T-cells to reduce antibody production. These approaches address the underlying autoimmune mechanism rather than just managing symptoms.

Myasthenia gravis impairs neuromuscular transmission by reducing functional nicotinic acetylcholine receptors at the neuromuscular junction. Antibody-mediated receptor destruction prevents normal acetylcholine signaling, disrupting the communication between motor neurons and skeletal muscles, resulting in progressive weakness and fatigability of skeletal muscles.

Myasthenia gravis is uniquely characterized by increased fatigability—muscle weakness worsens with activity and improves with rest. This autoimmune etiology, involving antibodies against nicotinic receptors, distinguishes it from primary muscle diseases. The condition's responsiveness to anticholinesterase drugs and immunosuppressive therapy further confirms its neuromuscular junction origin.